玻璃体腔注射抗血管内皮生长因子药物相关全身不良事件系统评价与荟萃分析的总览
该总览纳入2011年1月1日至2016年6月30日发表的21篇系统评价,评估玻璃体腔注射抗血管内皮生长因子(anti-VEGF)药物治疗新生血管性年龄相关性黄斑变性、糖尿病黄斑水肿或视网膜静脉阻塞患者的全身不良事件。结果显示抗VEGF治疗与对照组相比未增加全身不良事件风险,按月给药与按需给药方案间无差异;贝伐珠单抗与雷珠单抗相比似乎未增加全身不良事件风险;雷珠单抗可能与年龄相关性黄斑变性患者非眼部出血风险增加相关。
要点
- 抗VEGF治疗与对照组相比未增加全身不良事件风险,按月给药与按需给药方案间无差异。
- 贝伐珠单抗与雷珠单抗相比似乎未增加全身不良事件风险。
- 雷珠单抗可能与年龄相关性黄斑变性患者非眼部出血风险增加相关。
核心结论
- 抗VEGF治疗未增加全身不良事件风险,但年龄相关性黄斑变性老年患者接受雷珠单抗时可能需谨慎,因其出血事件风险可能较高。
研究设计与样本
- 系统检索PubMed和Cochrane对照试验中心注册库,纳入系统评价和荟萃分析,共检索到2011年1月1日至2016年6月30日发表的21篇系统评价。
- 其中11篇以全身不良事件为主要结局,采用PRISMA清单和AMSTAR清单(版本1)评估质量。
主要发现
- PRISMA和AMSTAR评分中位数(四分位距)分别为23/27(15-27)和8/11(5-11),但5篇综述(25%)评分分别低于20和7。
- 所有综述均使用客观量表评估纳入研究的偏倚风险,最常用Cochrane偏倚风险工具(16篇综述[76%])。
- 抗VEGF治疗与对照组相比未增加全身不良事件风险;按月给药与按需给药方案间全身不良事件无增加。
- 与雷珠单抗相比,贝伐珠单抗在最新和最详尽的综述中似乎未增加全身不良事件风险。
- 与对照治疗相比,雷珠单抗可能与年龄相关性黄斑变性患者非眼部出血风险增加相关。
关键数值与推荐
- PRISMA评分中位数23/27(15-27),AMSTAR评分中位数8/11(5-11)。
- 5篇综述(25%)PRISMA评分低于20,AMSTAR评分低于7。
- 16篇综述(76%)使用Cochrane偏倚风险工具。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The systemic safety of intravitreal anti-vascular endothelial growth factor (anti-VEGF) medications is still a matter of debate. OBJECTIVE: This overview of systematic reviews evaluates systemic adverse events associated with intravitreal anti-VEGF treatments in patients with neovascular age-related macular degeneration, diabetic macular edema, or retinal vein occlusion. DESIGN, EVIDENCE, AND REPORTING: This systematic search of PubMed and the Cochrane Central Register of Controlled Trials database includes meta-analyses and systematic reviews. We describe the summary measures of association between anti-VEGF treatments and outcomes reported in each systematic review. MAIN OUTCOMES AND MEASURES: The quality of the systematic reviews was assessed with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist and A Measurement Tool to Assess Systematic Reviews (AMSTAR) checklist, version 1. FINDINGS: We retrieved 21 systematic reviews published between January 1, 2011, and June 30, 2016. Of these, 11 analyzed systemic adverse events as the primary outcome. The median (interquartile range) PRISMA and AMSTAR scores were 23 of 27 (15-27) and 8 of 11 (5-11), respectively, but 5 reviews (25%) scored below 20 and 7, respectively. All reviews used an objective scale to assess methodological risk of bias in their included studies, the Cochrane Risk of Bias Tool being the most commonly used (16 reviews [76%]). Anti-VEGF treatments did not increase the risk of systemic adverse events when compared with control regimens; similarly, there was no increase in systematic adverse events when treatment was given on a monthly schedule vs an as-needed regimen. Compared with ranibizumab, bevacizumab did not appear to be associated with an increase in the risk of systemic adverse events in the most recent and exhaustive reviews. Compared with control treatments, ranibizumab may be associated with an increase in the risk of nonocular hemorrhage in patients with age-related macular degeneration. CONCLUSIONS AND RELEVANCE: This overview of reviews and meta-analyses suggest that anti-VEGF treatments do not increase the risk of systemic adverse events, but that caution might be advisable in older patients with age-related macular degeneration who may be at higher risk of hemorrhagic events when receiving ranibizumab.
引用
- Thulliez M, Angoulvant D, Pisella PJ, et al. Overview of Systematic Reviews and Meta-analyses on Systemic Adverse Events Associated With Intravitreal Anti-Vascular Endothelial Growth Factor Medication Use. JAMA Ophthalmol. 2018. PMID: 29566105. doi:10.1001/jamaophthalmol.2018.0002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。